October 2026
M	T	W	T	F	S	S
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Edward Lee Carter: A 15-Minute Blood Test for Brain Hemorrhage?

Edward Lee Carter/LinkedIn

Oct 18, 2026, 16:38

Edward Lee Carter: A 15-Minute Blood Test for Brain Hemorrhage?

Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, stared a post on LinkedIn:

”A 15-Minute Blood Test for Brain Hemorrhage?

Promising Science, Important Limitations.

Could a simple blood test eventually help emergency teams identify intracranial hemorrhage before a patient reaches the hospital?

A study published October 15 in JAMA Network Open evaluated prehospital point-of-care testing for glial fibrillary acidic protein (GFAP), a biomarker released following astroglial injury.

Researchers studied 65 adults with severe acute nontraumatic coma.

CT imaging confirmed intracranial hemorrhage in 33 patients.

The findings were impressive:

97.0 percent sensitivity — 32 of 33 hemorrhages detected
53.1 percent specificity
94.4 percent negative predictive value
Approximately 15-minute assay turnaround

But the numbers deserve closer examination.

One hemorrhage was missed—and it was an isolated subarachnoid hemorrhage.

Additionally, 15 patients without intracranial hemorrhage had positive GFAP results.

That distinction matters. A highly sensitive test is not necessarily a reliable standalone rule-out test, particularly when a missed diagnosis could have devastating consequences.

Why is this important for rural healthcare?

In communities where advanced stroke and neurosurgical services may be hours away, decisions about transporting critically ill patients to the nearest hospital versus a specialized center can significantly influence care.

A rapid blood biomarker could eventually help inform those decisions.

But this study did not demonstrate improved transport decisions, survival, or neurologic outcomes.

There are also implications for antithrombotic stewardship.

For patients receiving warfarin or direct oral anticoagulants, early recognition of intracranial hemorrhage is essential to timely imaging, specialist evaluation, and appropriate reversal when indicated.

However, GFAP does not measure anticoagulant activity, cannot replace CT imaging, and should not independently determine whether reversal therapy is administered.

Limitations remain.

This was a small, highly selected population of severely ill patients managed by a specialized prehospital critical care service.

The reported negative predictive value also reflects a population in which approximately half the patients had intracranial hemorrhage. These results should not be generalized to routine stroke presentations.

Larger prospective studies must determine whether GFAP-guided care improves triage, reduces delays, and ultimately improves patient outcomes.

Takeaway:

Promising detection does not automatically translate into proven clinical benefit.

A test with 97 percent sensitivity deserves attention.

But even one missed hemorrhage matters when the stakes are this high.

The goal is not simply earlier diagnostic information.

It is earlier, safer decisions that lead to better patient outcomes.

The views expressed are my own and do not represent the official positions of the Department of Veterans Affairs or the U.S. government.”

Edward Lee Carter: A 15-Minute Blood Test for Brain Hemorrhage?